We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+17.69%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$9.21M
Cap. Flow
+$6.26M
Cap. Flow %
4.65%
Top 10 Hldgs %
39.93%
Holding
69
New
12
Increased
31
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$3.25M
2
AXSM icon
Axsome Therapeutics
AXSM
+$1.28M
3
HRTX icon
Heron Therapeutics
HRTX
+$439K
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$435K
5
SCYX icon
SCYNEXIS
SCYX
+$419K

Top Sells

Rank Stock Value
1
QGENF
QIAGEN NV
QGENF
+$3.13M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$809K
3
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$249K

Sector Composition

Rank Sector Weight
1 Healthcare 77.47%
2 Miscellaneous 21.89%
3 Real Estate 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
CALL
Bristol-Myers Squibb
BMY
$137B
$2.45M 1.82%
45,000
– –
PCRX icon
27
Pacira BioSciences
PCRX
$1.03B
$2.28M 1.69%
50,000
– –
ALXN
28
DELISTED
Alexion Pharmaceuticals
ALXN
$2.27M 1.68%
18,701
-6,272
-25% -$809K
CLVS
29
DELISTED
Clovis Oncology, Inc.
CLVS
$1.91M 1.42%
30,000
– –
PRTK
30
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.54M 1.14%
80,000
– –
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$1.54M 1.14%
10,000
– –
MDCO
32
DELISTED
Medicines Co
MDCO
$1.37M 1.02%
28,000
– –
LLY icon
33
CALL
Eli Lilly
LLY
$1.05T
$1.26M 0.94%
15,000
– –
ADMS
34
DELISTED
Adamas Pharmaceuticals
ADMS
$1.05M 0.78%
60,000
– –
AXSM icon
35
Axsome Therapeutics
AXSM
$10.8B
$1.04M 0.77%
+267,000
New +$1.28M
PTLA
36
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$980K 0.73%
25,000
– –
SNR
37
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$854K 0.63%
83,700
– –
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.59B
$827K 0.61%
12,201
+1,337
+12% +$102K
GILD icon
39
CALL
Gilead Sciences
GILD
$185B
$679K 0.5%
+10,000
New +$703K
CFRX
40
DELISTED
ContraFect Corporation
CFRX
$540K 0.4%
375
– –
HRTX icon
41
Heron Therapeutics
HRTX
$63M
$476K 0.35%
+31,748
New +$439K
KITE
42
DELISTED
Kite Pharma, Inc.
KITE
$466K 0.35%
5,931
+564
+11% +$34.9K
SCTL
43
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$441K 0.33%
56,266
+11,666
+26% +$81.2K
LABU icon
44
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
$416K 0.31%
436
-279
-39% -$249K
GRFS
45
Grifois
GRFS
$5.32B
$414K 0.31%
21,932
+5,319
+32% +$92.3K
PGNX
46
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$411K 0.31%
+43,565
New +$435K
IQV icon
47
IQVIA
IQV
$43.2B
$405K 0.3%
5,027
+1,609
+47% +$126K
JUNO
48
DELISTED
Juno Therapeutics, Inc.
JUNO
$400K 0.3%
18,030
+6,552
+57% +$141K
CRL icon
49
Charles River Laboratories
CRL
$14.2B
$399K 0.3%
4,441
+1,138
+34% +$96.7K
NBIX icon
50
Neurocrine Biosciences
NBIX
$15.8B
$398K 0.3%
9,184
+3,047
+50% +$131K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2017 Portfolio in Review

As of Q1 2017, Opus Point Partners Management held 69 positions worth $135M, up 7.3% from $126M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Opus Point Partners Management deployed $6.26M of net new capital in Q1 2017, opening 12 new positions and adding to 31 existing holdings. Its largest new stake was Qiagen: 105,399 shares worth $3.24M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $809K trimmed.

  • Opus Point Partners Management's largest Q1 2017 buy was Qiagen: 105,399 shares worth $3.24M.
  • Opus Point Partners Management added most to Precigen in Q1 2017, an estimated $189K increase.
  • Opus Point Partners Management's biggest Q1 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $809K.
  • Opus Point Partners Management fully exited QIAGEN NV in Q1 2017, selling an estimated $3.13M.
  • Opus Point Partners Management's ten largest holdings make up 40% of its $135M portfolio in Q1 2017.
  • Opus Point Partners Management opened 12 new positions and closed 2 in Q1 2017.
  • Opus Point Partners Management's portfolio value rose 7.3% quarter-over-quarter to $135M.

Based on Opus Point Partners Management's 13F filing for Q1 2017, filed 15 May 2017.